As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
19 February 2026 | Learn the fundamentals of the HALO GraphQL API and how to design, develop, and implement time-saving automations
Designing and Developing Automated Solutions Using the HALO GraphQL API Read More »
22 January 2026 | Learn how HALO and HALO AI are helping expand our understanding of immune regulation by different subtypes of cancer-associated fibroblasts!
Highly multiplexed imaging reveals CAF-immune cell niches in cutaneous carcinomas Read More »
As scientists work to continue unraveling the structural, cellular, and molecular complexities of the brain and its diseases, the characteristics of this unique tissue pose significant challenges to traditional histological analysis.
Advancing Neuroscience Research with HALO® and HALO AI Read More »
We’re excited to announce the launch of the newly updated Muscle Fiber BF and Muscle Fiber FL modules supporting AI nuclear segmentation, AI membrane segmentation, interactive markups, and new output metrics..
ALBUQUERQUE, NM, and VISTA, CA, December 3, 2025 – Indica Labs, the global leader of AI-powered digital pathology, and Leica Biosystems, a global leader in anatomic and digital pathology solutions, announced today that the Food and Drug Administration (FDA) has issued a 510(k) clearance for the enterprise digital pathology platform HALO AP Dx in conjunction with Leica Biosystems Aperio GT 450 DX Scanner for in-vitro diagnostic use.
Adam Smith shares his journey from being a HALO® customer to helping lead Indica Labs’ mission of making AI accessible to pathologists everywhere.
People of Pathology Podcast: Adam Smith – Making AI Accessible For All With Indica Labs Read More »
Antibody-drug conjugates (ADC) represent one of the most promising classes of next-generation cancer therapeutics, combining antibody-based targeting with the potency of chemotherapy.
